SPONSOR
Chinese PLA General Hospital
Total Trials
9
Recruiting
9
Phases
Phase 4, Phase 1, Phase 2
Conditions studied: Hepatocellular CarcinomaNeuromyelitis Optica Spectrum Disorder AttackMultiple MyelomaNephropathyGlomerular DiseasesIdiopathic Membranous NephropathyDiabetic NephropathyT2DMLower Urinary Tract SymptomsIgA Glomerulonephritis
Chinese PLA General Hospital is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Hepatocellular Carcinoma, Neuromyelitis Optica Spectrum Disorder Attack, Multiple Myeloma, Nephropathy.
The trial portfolio spans Phase 4, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chinese PLA General Hospital
How many clinical trials has Chinese PLA General Hospital sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Chinese PLA General Hospital, of which 9 are actively recruiting participants. These trials cover conditions including Hepatocellular Carcinoma, Neuromyelitis Optica Spectrum Disorder Attack, Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chinese PLA General Hospital research focus on?
Chinese PLA General Hospital clinical trials span Hepatocellular Carcinoma, Neuromyelitis Optica Spectrum Disorder Attack, Multiple Myeloma, Nephropathy, Glomerular Diseases, and additional conditions. The research pipeline includes Phase 4, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chinese PLA General Hospital clinical trial?
To participate in a Chinese PLA General Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chinese PLA General Hospital trials with current recruitment status updated daily.
Clinical Trials by Chinese PLA General Hospital
NCT04365751
Recruiting
To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
Hepatocellular Carcinoma
NCT07410039 Phase 4
Recruiting
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
Neuromyelitis Optica Spectrum Disorder Attack
NCT07620275 Phase 1
Recruiting
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Multiple Myeloma
NCT05839314 Phase 4
Recruiting
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
Nephropathy
NCT06843304
Recruiting
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Diabetic Nephropathy
NCT06352736
Recruiting
Status of Disease Burden of Lower Urinary Tract Symptoms in Chinese Male Community
Lower Urinary Tract Symptoms
NCT07585981
Recruiting
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
IgA Glomerulonephritis
NCT06084819 Phase 2
Recruiting
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
NCT05833893 Phase 2
Recruiting
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
nk/T-cell Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology